Simurosertib is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 150 | |
4 mg | In stock | $ 255 | |
8 mg | In stock | $ 378 | |
20 mg | In stock | $ 875 | |
40 mg | In stock | $ 1382 |
Description | Simurosertib is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM). |
Targets&IC50 | Cdc7:<0.3 nM |
In vitro | Simurosertib effectively inhibits CDC7 kinase activity (IC50 120-fold selectivity of Simurosertib for CDC7 kinase inhibition compared to other kinase inhibitions . |
In vivo | Simurosertib (p.o.) inhibits pMCM2 of the xenografted COLO205 in a dose- and time-dependent manner in the COLO205-xenograft mouse model. Simurosertib shows a significant antitumor activity in multiple xenograft models . |
Synonyms | TAK-931 |
CAS No. | 1330782-76-7 |
Chemical Formula | C17H19N5OS |
Molecular Weight | 341.43 |
Solubility | DMSO: 75 mg/mL (219.66 mM), Need ultrasonic |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom